Fallopian Tube Cancer – Pipeline Review, H1 2012

Introduction

Global Markets Direct’s, 'Fallopian Tube Cancer - Pipeline Review, H1 2012', provides an overview of the Fallopian Tube Cancer therapeutic pipeline. This report provides information on the therapeutic development for Fallopian Tube Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer. 'Fallopian Tube Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Fallopian Tube Cancer.
- A review of the Fallopian Tube Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Fallopian Tube Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Highlights

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Fallopian Tube Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Fallopian Tube Cancer pipeline depth and focus of Fallopian Tube Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
[Studien Infos ausblenden]

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Fallopian Tube Cancer Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Fallopian Tube Cancer 11
Fallopian Tube Cancer Therapeutics under Development by Companies 13
Fallopian Tube Cancer Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 22
Comparative Analysis 22
Mid Clinical Stage Products 23
Comparative Analysis 23
Early Clinical Stage Products 24
Comparative Analysis 24
Fallopian Tube Cancer Therapeutics – Products under Development by Companies 25
Fallopian Tube Cancer Therapeutics – Products under Investigation by Universities/Institutes 28
Companies Involved in Fallopian Tube Cancer Therapeutics Development 39
Boehringer Ingelheim GmbH 39
F. Hoffmann-La Roche Ltd. 40
Abbott Laboratories 41
Amgen Inc. 42
Sanofi-Aventis 43
Eli Lilly and Company 44
Takeda Pharmaceutical Company Limited 45
Millennium Pharmaceuticals, Inc. 46
Novartis AG 47
ImClone Systems Incorporated 48
Cell Therapeutics, Inc. 49
EntreMed, Inc. 50
Novogen Limited 51
Oncolytics Biotech Inc. 52
TopoTarget A/S 53
Synta Pharmaceuticals Corp. 54
Oasmia Pharmaceutical AB 55
MabVax Therapeutics, Inc. 56
BiPar Sciences, Inc. 57
ImmunoVaccine Technologies Inc. 58
TRACON Pharmaceuticals, Inc. 59
RECEPTA Biopharma S.A. 60
Fallopian Tube Cancer – Therapeutics Assessment 61
Assessment by Monotherapy Products 61
Assessment by Combination Products 62
Assessment by Route of Administration 63
Assessment by Molecule Type 65
Drug Profiles 68
AMG 386 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
OPAXIO - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Paclical - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Phenoxodiol + Carboplatin - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Bevacizumab + Carboplatin + Gemcitabine - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Carboplatin + Paclitaxel + Bevacizumab - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Carboplatin + Paclitaxel + Bevacizumab - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Oxaliplatin + Capecitabine + Bevacizumab - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Carboplatin + Gemcitabine + Paclitaxel - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Carboplatin + Paclitaxel - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Carboplatin + Ifosfamide - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Carboplatin + Ifosfamide + Whole Body Hyperthermia - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Carboplatin + Paclitaxel + Cediranib - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Carboplatin + Paclitaxel - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Carboplatin - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Bevacizumab + Carboplatin + Docetaxel + Paclitaxel - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Paclitaxel - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Taxol + Paraplatin - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
AMG 386 + Pegylated Liposomal Doxorubicin - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
AMG 386 + Paclitaxel - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Carboplatin + Gemcitabine Hydrochloride + Paclitaxel - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 105
Avastin + Carboplatin + Paclitaxel - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
Avastin + Carboplatin + Paclitaxel - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
Avastin + Paclitaxel + Topotecan + Liposomal Doxorubicin - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
Bevacizumab + Cisplatin + Paclitaxel - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 112
Cisplatin + Carboplatin - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
Taxol + Paraplatin + Bevacizumab - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
Paclitaxel + Carboplatin + Epirubicin - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 118
Paclitaxel + AZD0530 - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
Bevacizumab + Carboplatin + Paclitaxel - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 121
OPT-821 + Polyvalent Antigen-KLH Conjugate Vaccine - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
Cisplatin + Topotecan + Paclitaxel + Carboplatin - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 125
Carboplatin + Glutathione + Paclitaxel - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
bevacizumab + capecitabine + carboplatin + oxaliplatin + paclitaxel - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 129
Carboplatin + Paclitaxel + Bevacizumab - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 132
Cisplatin + Paclitaxel - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 133
CT-2103 - Drug Profile 134
Product Description 134
Mechanism of Action 134
R&D Progress 134
Fallopian Tube Cancer Therapeutics – Drug Profile Updates 136
Fallopian Tube Cancer Therapeutics – Discontinued Products 140
Fallopian Tube Cancer Therapeutics - Dormant Products 142
Fallopian Tube Cancer – Product Development Milestones 146
Featured News & Press Releases 146
Nov 01, 2010: Synta Announces Gynecologic Oncology Group To Initiate Phase II Clinical Trial Of Elesclomol For Treatment Of Ovarian Cancer 146
Nov 01, 2010: Synta Announces Gynecologic Oncology Group To Initiate Phase II Clinical Trial Of Elesclomol For Treatment Of Ovarian Cancer 146
Sep 02, 2010: Oncolytics Biotech Announces Phase II Ovarian Cancer Study To Be Conducted By Gynecologic Oncology Group 147
Appendix 149
Methodology 149
Coverage 149
Secondary Research 149
Primary Research 149
Expert Panel Validation 150
Contact Us 150
Disclaimer 150
[Inhaltsverzeichnis ausblenden]

List of Tables
Number of Products Under Development for Fallopian Tube Cancer, H1 2012 11
Products under Development for Fallopian Tube Cancer – Comparative Analysis, H1 2012 12
Number of Products under Development by Companies, H1 2012 14
Number of Products under Development by Companies, H1 2012 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2012 17
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 18
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 20
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 21
Comparative Analysis by Late Stage Development, H1 2012 22
Comparative Analysis by Mid Clinical Stage Development, H1 2012 23
Comparative Analysis by Early Clinical Stage Development, H1 2012 24
Products under Development by Companies, H1 2012 25
Products under Development by Companies, H1 2012 (Contd..1) 26
Products under Development by Companies, H1 2012 (Contd..2) 27
Products under Investigation by Universities/Institutes, H1 2012 28
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 29
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 30
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 31
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 32
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 33
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 34
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 35
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 36
Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 37
Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 38
Boehringer Ingelheim GmbH, H1 2012 39
F. Hoffmann-La Roche Ltd., H1 2012 40
Abbott Laboratories, H1 2012 41
Amgen Inc., H1 2012 42
Sanofi-Aventis, H1 2012 43
Eli Lilly and Company, H1 2012 44
Takeda Pharmaceutical Company Limited, H1 2012 45
Millennium Pharmaceuticals, Inc., H1 2012 46
Novartis AG, H1 2012 47
ImClone Systems Incorporated, H1 2012 48
Cell Therapeutics, Inc., H1 2012 49
EntreMed, Inc., H1 2012 50
Novogen Limited, H1 2012 51
Oncolytics Biotech Inc., H1 2012 52
TopoTarget A/S, H1 2012 53
Synta Pharmaceuticals Corp., H1 2012 54
Oasmia Pharmaceutical AB, H1 2012 55
MabVax Therapeutics, Inc., H1 2012 56
BiPar Sciences, Inc., H1 2012 57
ImmunoVaccine Technologies Inc., H1 2012 58
TRACON Pharmaceuticals, Inc., H1 2012 59
RECEPTA Biopharma S.A., H1 2012 60
Assessment by Monotherapy Products, H1 2012 61
Assessment by Combination Products, H1 2012 62
Assessment by Stage and Route of Administration, H1 2012 64
Assessment by Molecule Type, H1 2012 67
Fallopian Tube Cancer Therapeutics – Drug Profile Updates 136
Fallopian Tube Cancer Therapeutics – Discontinued Products 140
Fallopian Tube Cancer Therapeutics – Discontinued Products (Contd..1) 141
Fallopian Tube Cancer Therapeutics – Dormant Products 142
Fallopian Tube Cancer Therapeutics – Dormant Products (Contd..1) 143
Fallopian Tube Cancer Therapeutics – Dormant Products (Contd..2) 144
Fallopian Tube Cancer Therapeutics – Dormant Products (Contd..3) 145
List of Figures
Number of Products under Development for Fallopian Tube Cancer, H1 2012 11
Products under Development for Fallopian Tube Cancer – Comparative Analysis, H1 2012 12
Products under Development by Companies, H1 2012 13
Products under Investigation by Universities/Institutes, H1 2012 16
Late Stage Products, H1 2012 22
Mid Clinical Stage Products, H1 2012 23
Early Clinical Stage Products, H1 2012 24
Assessment by Monotherapy Products, H1 2012 61
Assessment by Combination Products, H1 2012 62
Assessment by Route of Administration, H1 2012 63
Assessment by Stage and Route of Administration, H1 2012 64
Assessment by Molecule Type, H1 2012 65
Assessment by Stage and Molecule Type, H1 2012 66
[Tabellenverzeichnis ausblenden]